HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.

Abstract
Diabetic retinopathy, a leading cause of vision loss in working-age population, is often associated with inflammation and apoptosis. We have previously reported that sitagliptin, a DPP-IV inhibitor, exerts beneficial effects in the retina of type 2 diabetic animals. The present study aimed to evaluate whether sitagliptin can exert protective effects in the retina of type 1 diabetic animals by a mechanism independent of insulin secretion and glycemia normalization. Streptozotocin-induced diabetic rats were treated orally with sitagliptin (5mg/kg/day) for the last two weeks of 4 weeks of diabetes. Sitagliptin treatment did not change the weight and glucose, HbA1c or insulin levels. However, it prevented the diabetes-induced increase in DPP-IV/CD26 activity and levels in serum and retina. Sitagliptin also prevented the increase in blood-retinal barrier (BRB) permeability and inhibited the changes in immunoreactivity and endothelial subcellular distribution of occludin, claudin-5 and ZO-1 proteins induced by diabetes. Furthermore, sitagliptin decreased the retinal inflammatory state and neuronal apoptosis. Sitagliptin inhibited the BRB breakdown in a type 1 diabetic animal model, by a mechanism independent of normalization of glycemia, by preventing changes in tight junctions (TJs) organization. Sitagliptin also exerted protective effects against inflammation and pro-apoptotic state in the retina of diabetic rats. Altogether, these results suggest that sitagliptin might be envisaged to be used to prevent or delay some of the alterations associated with the development of diabetic retinopathy.
AuthorsAndreia Gonçalves, Catarina Marques, Ermelindo Leal, Carlos F Ribeiro, Flávio Reis, António F Ambrósio, Rosa Fernandes
JournalBiochimica et biophysica acta (Biochim Biophys Acta) Vol. 1842 Issue 9 Pg. 1454-63 (Sep 2014) ISSN: 0006-3002 [Print] Netherlands
PMID24769045 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Biomarkers
  • Dipeptidyl-Peptidase IV Inhibitors
  • Pyrazines
  • Triazoles
  • Dipeptidyl Peptidase 4
  • Sitagliptin Phosphate
Topics
  • Animals
  • Apoptosis
  • Biomarkers (analysis)
  • Blood-Retinal Barrier (drug effects, metabolism)
  • Blotting, Western
  • Cell Death
  • Cells, Cultured
  • Diabetes Mellitus, Experimental (drug therapy, metabolism, pathology)
  • Diabetes Mellitus, Type 1 (drug therapy, metabolism, pathology)
  • Diabetic Retinopathy (drug therapy, metabolism, pathology)
  • Dipeptidyl Peptidase 4 (chemistry, metabolism)
  • Dipeptidyl-Peptidase IV Inhibitors (pharmacology)
  • Enzyme-Linked Immunosorbent Assay
  • Immunoenzyme Techniques
  • Inflammation (drug therapy, metabolism, pathology)
  • Male
  • Neurons (drug effects, metabolism, pathology)
  • Pyrazines (pharmacology)
  • Rats
  • Rats, Wistar
  • Retina (drug effects, metabolism, pathology)
  • Sitagliptin Phosphate
  • Triazoles (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: